Literature DB >> 20387148

Short hairpin RNA (shRNA): design, delivery, and assessment of gene knockdown.

Chris B Moore1, Elizabeth H Guthrie, Max Tze-Han Huang, Debra J Taxman.   

Abstract

Shortly after the cellular mechanism of RNA interference (RNAi) was first described, scientists began using this powerful technique to study gene function. This included designing better methods for the successful delivery of small interfering RNAs (siRNAs) and short hairpin RNAs (shRNAs) into mammalian cells. While the simplest method for RNAi is the cytosolic delivery of siRNA oligonucleotides, this technique is limited to cells capable of transfection and is primarily utilized during transient in vitro studies. The introduction of shRNA into mammalian cells through infection with viral vectors allows for stable integration of shRNA and long-term knockdown of the targeted gene; however, several challenges exist with the implementation of this technology. Here we describe some well-tested protocols which should increase the chances of successful design, delivery, and assessment of gene knockdown by shRNA. We provide suggestions for designing shRNA targets and controls, a protocol for sequencing through the secondary structure of the shRNA hairpin structure, and protocols for packaging and delivery of shRNA lentiviral particles. Using real-time PCR and functional assays we demonstrate the successful knockdown of ASC, an inflammatory adaptor molecule. These studies demonstrate the practicality of including two shRNAs with different efficacies of knockdown to provide an additional level of control and to verify dose dependency of functional effects. Along with the methods described here, as new techniques and algorithms are designed in the future, shRNA is likely to include further promising application and continue to be a critical component of gene discovery.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20387148      PMCID: PMC3679364          DOI: 10.1007/978-1-60761-657-3_10

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  23 in total

1.  Rational siRNA design for RNA interference.

Authors:  Angela Reynolds; Devin Leake; Queta Boese; Stephen Scaringe; William S Marshall; Anastasia Khvorova
Journal:  Nat Biotechnol       Date:  2004-02-01       Impact factor: 54.908

2.  Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference.

Authors:  Kumiko Ui-Tei; Yuki Naito; Fumitaka Takahashi; Takeshi Haraguchi; Hiroko Ohki-Hamazaki; Aya Juni; Ryu Ueda; Kaoru Saigo
Journal:  Nucleic Acids Res       Date:  2004-02-09       Impact factor: 16.971

3.  An algorithm for selection of functional siRNA sequences.

Authors:  Mohammed Amarzguioui; Hans Prydz
Journal:  Biochem Biophys Res Commun       Date:  2004-04-16       Impact factor: 3.575

4.  miRNA, siRNA, piRNA: Knowns of the unknown.

Authors:  Claudia Kutter; Petr Svoboda
Journal:  RNA Biol       Date:  2008-10-16       Impact factor: 4.652

5.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.

Authors:  A Fire; S Xu; M K Montgomery; S A Kostas; S E Driver; C C Mello
Journal:  Nature       Date:  1998-02-19       Impact factor: 49.962

6.  A human, ATP-independent, RISC assembly machine fueled by pre-miRNA.

Authors:  Elisavet Maniataki; Zissimos Mourelatos
Journal:  Genes Dev       Date:  2005-12-15       Impact factor: 11.361

7.  Impact of preimmunization on adenoviral vector expression and toxicity in a subcutaneous mouse cancer model.

Authors:  Maria T Vlachaki; Andres Hernandez-Garcia; Michael Ittmann; Madhu Chhikara; Laura K Aguilar; Xiaohong Zhu; Bin S Teh; E Brain Butler; Shiao Woo; Timothy C Thompson; Hugo Barrera-Saldana; Estuardo Aguilar-Cordova; Bin S The
Journal:  Mol Ther       Date:  2002-09       Impact factor: 11.454

8.  siRNA-mediated gene silencing in vitro and in vivo.

Authors:  Haibin Xia; Qinwen Mao; Henry L Paulson; Beverly L Davidson
Journal:  Nat Biotechnol       Date:  2002-09-16       Impact factor: 54.908

9.  Critical role of apoptotic speck protein containing a caspase recruitment domain (ASC) and NLRP3 in causing necrosis and ASC speck formation induced by Porphyromonas gingivalis in human cells.

Authors:  Max Tze-Han Huang; Debra J Taxman; Elizabeth A Holley-Guthrie; Chris B Moore; Stephen B Willingham; Victoria Madden; Rebecca Keyser Parsons; Gerald L Featherstone; Roland R Arnold; Brian P O'Connor; Jenny Pan-Yun Ting
Journal:  J Immunol       Date:  2009-02-15       Impact factor: 5.422

10.  In vivo silencing of alpha-synuclein using naked siRNA.

Authors:  Jada Lewis; Heather Melrose; David Bumcrot; Andrew Hope; Cynthia Zehr; Sarah Lincoln; Adam Braithwaite; Zhen He; Sina Ogholikhan; Kelly Hinkle; Caroline Kent; Ivanka Toudjarska; Klaus Charisse; Ravi Braich; Rajendra K Pandey; Michael Heckman; Demetrius M Maraganore; Julia Crook; Matthew J Farrer
Journal:  Mol Neurodegener       Date:  2008-11-01       Impact factor: 14.195

View more
  86 in total

1.  Human U6 promoter drives stronger shRNA activity than its schistosome orthologue in Schistosoma mansoni and human fibrosarcoma cells.

Authors:  Raphaël Duvoisin; Mary A Ayuk; Gabriel Rinaldi; Sutas Suttiprapa; Victoria H Mann; Clarence M Lee; Nicola Harris; Paul J Brindley
Journal:  Transgenic Res       Date:  2011-09-28       Impact factor: 2.788

2.  BMP-2, hypoxia, and COL1A1/HtrA1 siRNAs favor neo-cartilage hyaline matrix formation in chondrocytes.

Authors:  David Ollitrault; Florence Legendre; Carole Drougard; Mélanie Briand; Hervé Benateau; Didier Goux; Hanane Chajra; Laurent Poulain; Daniel Hartmann; Denis Vivien; Vijayalakshmi Shridhar; Alfonso Baldi; Frédéric Mallein-Gerin; Karim Boumediene; Magali Demoor; Philippe Galera
Journal:  Tissue Eng Part C Methods       Date:  2014-07-31       Impact factor: 3.056

3.  In vitro study on shRNA-mediated reduction of testis developmental related gene 1 expression and its effects on the proliferation, invasion and apoptosis of NTERA-2 cells.

Authors:  Y U Gan; Jianfu Yang; Yong Wang; Zhengyu Tan; Xianzhen Jiang; Yuxin Tang
Journal:  Oncol Lett       Date:  2015-05-18       Impact factor: 2.967

4.  Prospects of siRNA cocktails as tools for modifying multiple gene targets in the injured spinal cord.

Authors:  Felicia Mary Michael; Preeja Chandran; Khaviyaa Chandramohan; Krithika Iyer; Kevin Jayaraj; Revathidevi Sundaramoorthy; Sankar Venkatachalam
Journal:  Exp Biol Med (Maywood)       Date:  2019-08-28

Review 5.  Nanoparticulate RNA delivery systems in cancer.

Authors:  Ankur Sharma; Niraj Kumar Jha; Kajal Dahiya; Vivek Kumar Singh; Kundan Chaurasiya; Aditya Narayan Jha; Saurabh Kumar Jha; Prabhu Chandra Mishra; Sunny Dholpuria; Rani Astya; Parma Nand; Amit Kumar; Janne Ruokolainen; Kavindra Kumar Kesari
Journal:  Cancer Rep (Hoboken)       Date:  2020-07-30

6.  Promoter cross-talk affects the inducible expression of intronic shRNAs from the tetracycline response element.

Authors:  Seong Kyun Park; Byung Joon Hwang; Yun Kee
Journal:  Genes Genomics       Date:  2019-01-17       Impact factor: 1.839

7.  Enzymatic construction of shRNA library from oligonucleotide library.

Authors:  Seong Kyun Park; Yun Kee; Taehoon Ryu; Hyoki Kim; Byung Joon Hwang
Journal:  Genes Genomics       Date:  2019-03-04       Impact factor: 1.839

Review 8.  Engineered Hydrogels for Local and Sustained Delivery of RNA-Interference Therapies.

Authors:  Leo L Wang; Jason A Burdick
Journal:  Adv Healthc Mater       Date:  2016-12-15       Impact factor: 9.933

9.  The NLR adaptor ASC/PYCARD regulates DUSP10, mitogen-activated protein kinase (MAPK), and chemokine induction independent of the inflammasome.

Authors:  Debra J Taxman; Elizabeth A Holley-Guthrie; Max Tze-Han Huang; Chris B Moore; Daniel T Bergstralh; Irving C Allen; Yu Lei; Denis Gris; Jenny Pan-Yun Ting
Journal:  J Biol Chem       Date:  2011-04-12       Impact factor: 5.157

Review 10.  Recent advances in RNAi-based strategies for therapy and prevention of HIV-1/AIDS.

Authors:  Manjunath N Swamy; Haoquan Wu; Premlata Shankar
Journal:  Adv Drug Deliv Rev       Date:  2016-03-21       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.